Serono in talks with top pharma companies about potential takeover

Share this article:
Serono has held talks with Novartis, GlaxoSmithKline, Sanofi-Aventis and Pfizer in recent weeks about a potential $15 billion takeover of the company, The Wall Street Journal reported today.
Serono, based in Geneva, Switzerland, is the world's third largest biotech company by sales.
In a statement, the company said that it has hired investment bank Goldman Sachs Group "to explore various strategic alternatives for the company," adding that "there can be no assurances that any transaction will be consummated."
Any buyer would most likely be interested in Serono's multiple sclerosis drug Rebif, which had sales of $1 billion in 2004. The company also sells drugs to treat infertility and is attempting to develop 30 new medicines for cancer, inflammatory diseases and other therapeutic areas.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...